901-P: COVALENT 112—A Clinical Trial Assessing BMF-219, an Oral Covalent Menin Inhibitor in Type 1 Diabetes
Bibliographic record
Abstract
Background and Aims: Inhibition of menin, a scaffold protein, results in beta cell proliferation and enhanced insulin secretion in T1D. BMF-219, an oral covalent menin inhibitor, is in clinical development for T1D and T2D. Based on ex-vivo islet microtissue data and preclinical animal models, we hypothesize BMF-219 treatment will result in beta-cell proliferation and improved insulin secretory capacity. Here we describe the design of the COVALENT-112, a Phase II trial assessing BMF-219 in adults with T1D (NCT06152042). Methods: COVALENT-112 consists of two parts. Part A is a single-arm, open-label study; Part B is a randomized, double-blind, placebo-controlled study. Both are enrolling adults with Stage 3 T1D (HbA1c 6.5-10.0%). Part A is enrolling participants into 2 cohorts: 1) diagnosed ≤3 years with C-peptide ≥0.2 nmol/L (n=20); 2) diagnosed 3 to 15 years with C-peptide ≥0.08 nmol/L (n=20). In each cohort, 10 participants will be treated with BMF-219 100mg once daily (QD) and 10 will be treated with 200mg QD as an adjunct to insulin therapy. Part B is a 3-arm study assessing BMF-219 100mg QD, 200mg QD, or placebo for 12 weeks in participants with a diagnosis of T1D ≤3 years and C-peptide ≥0.2 nmol/L. In both Parts A and B, BMF-219 treatment duration will be 12 weeks, with a 40-week follow-up (52 weeks total). Key endpoints include change from baseline in stimulated C-peptide, insulin dose, and HbA1c. CGM will be utilized frequently, and safety, including hypoglycemia, will be assessed throughout the 52-week trial. Results: Initial results of the open-label study are expected in 2024; results of the double-blind, placebo-controlled study are expected in 2025. COVALENT-112 study is ongoing in the US and Canada. Conclusions: BMF-219 is a novel oral covalent menin inhibitor. In preclinical studies, it has demonstrated beta cell proliferation. COVALENT-112 assesses the efficacy and safety of 12-week QD BMF-219 in Stage 3 T1D, potentially addressing an important unmet need in this patient population. Disclosure H.T. Tran: None. D. Katselnik: None. D.S. Denham: None. M.K. Stevens-Brogan: None. C.W. Decker: None. S. Mourya: None. J.P. Frias: Research Support; Akero Therapeutics, Inc. Consultant; Akero Therapeutics, Inc. Research Support; Altimmune Inc. Consultant; Altimmune Inc. Research Support; Boehringer-Ingelheim. Consultant; Boehringer-Ingelheim. Research Support; 89bio, Inc. Consultant; 89bio, Inc. Research Support; Eli Lilly and Company. Advisory Panel; Eli Lilly and Company. Speaker's Bureau; Eli Lilly and Company. Research Support; Merck & Co., Inc. Consultant; Merck & Co., Inc. Research Support; Novartis Pharmaceuticals Corporation. Consultant; Novartis Pharmaceuticals Corporation, Novo Nordisk. Board Member; Novo Nordisk. Research Support; Novo Nordisk, Pfizer Inc. Consultant; Pfizer Inc. Advisory Panel; Sanofi. Speaker's Bureau; Sanofi. Research Support; Sanofi. Stock/Shareholder; Biomea Fusion, Inc. Employee; Biomea Fusion, Inc. T. Butler: Employee; Biomea Fusion, Inc. Board Member; Biomea Fusion, Inc. C.B. Guzman: None.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.001 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.002 | 0.002 |
| Insufficient payload (model declined to judge) | 0.009 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".